Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7126 to 7140 of 7706 results

  1. Adalimumab, etanercept and infliximab for ankylosing spondylitis (TA143)

    This guidance has been updated and replaced by NICE technology appraisal guidance 383.

    Technology appraisal guidance
    Published
    28 May 2008

  2. Rimonabant for the treatment of overweight and obese adults (TA144)

    This appraisal has been withdrawn. This is because the marketing authorisation for rimonabant was withdrawn on 16 January 2009.

    Technology appraisal guidance
    Published
    23 June 2008

  3. Bevacizumab for the first-line treatment of metastatic breast cancer (TA147)

    This appraisal has been updated and replaced by NICE technology appraisal 214.

    Technology appraisal guidance
    Published
    25 June 2008

  4. Zanamivir for the treatment of influenza in adults (TA15)

    This guidance has been replaced by NICE technology appraisal guidance 58 [Replaced by NICE technology appraisal guidance 168].

    Technology appraisal guidance
    Published
    27 November 2000

  5. Cetuximab for the treatment of metastatic colorectal cancer following failure of oxaliplatin-containing chemotherapy (TA150)

    This appraisal has been updated and replaced by NICE technology appraisal guidance 242.

    Technology appraisal guidance
    Published
    25 June 2008

  6. The clinical and cost effectiveness of pegylated interferon alpha 2a and alpha 2b for hepatitis C (TA14)

    This guidance has been replaced by NICE technology appraisal guidance 75.

    Technology appraisal guidance
    Published
    28 October 2000

  7. UrgoStart for chronic wounds (MIB82)

    This advice has been updated and replaced by NICE medical technologies guidance 42.

    Medtech innovation briefing
    Published
    5 October 2016

  8. Chronic kidney disease: managing anaemia (NG8)

    This guidance has been updated and replaced by NICE guideline NG203.

    NICE guideline
    Published
    3 June 2015

  9. Stop smoking interventions and services (NG92)

    This guideline has been updated and replaced by the NICE guideline on tobacco: preventing uptake, promoting quitting and treating dependence (NG209).

    NICE guideline
    Published
    28 March 2018

  10. Human growth hormone for the treatment growth failure in children (TA42)

    This guidance has been updated and replaced by NICE technology appraisal guidance 188. 

    Technology appraisal guidance
    Published
    27 May 2002

  11. Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (TA416)

    This guidance has been updated and replaced by NICE technology appraisal guidance 653.

    Technology appraisal guidance
    Published
    26 October 2016

  12. The clinical effectiveness and cost effectiveness of routine anti-D prophylaxis for RhD-negative women in pregnancy (TA41)

    This guidance has been updated and replaced by NICE technology appraisal guidance 156. 

    Technology appraisal guidance
    Published
    27 May 2002

  13. TheraSphere for treating operable and inoperable hepatocellular carcinoma (MIB62)

    This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.

    Medtech innovation briefing
    Published
    30 March 2016

  14. SIR-Spheres for treating inoperable hepatocellular carcinoma (MIB63)

    This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.

    Medtech innovation briefing
    Published
    30 March 2016

  15. Ultroid 2.0 for internal haemorrhoids (MIB75)

    This medtech innovation briefing is temporarily unavailable, please contact mibs@nice.org.uk for further information.

    Medtech innovation briefing
    Published
    26 July 2016